BioWorld

May 30, 2008

Kosan's Cancer Pipeline Attracts $5.50 Per Share BMS Buyout Bid

Kosan Biosciences Inc. is being snatched up by Bristol-Myers Squibb Co. for $5.50 per share, becoming the latest acquisition as big pharma struggles to fill dwindling pipelines. (BioWorld Today) Read More

FDA Documents Critical of Ligand's Promacta

Onconase Misses Endpoint, Rolling NDA to Proceed

NewCo News: EnzymeRx Makes a $14 Million Start with Uricase Acquisition

Drug Labeling Rule Proposed for Those Pregnant, Breastfeeding

Favrille Laying Off 132 After Specifid Fails Pivotal Trial

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 16, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

EHA 2026: With new lenses, a changing view on pediatric cancers

BioWorld

In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...

Medical illustration showing layers of a blood vessel

Anti-C5aR1 antibodies linked to outcomes in giant cell arteritis

BioWorld Science

More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways...

Fortvita and Innovent patent new anti-TROP2/B7-H4 ADCs

BioWorld Science

Fortvita Biologics Inc. and Innovent Biologics (Suzhou) Co. Ltd. have jointly reported new antibody-drug conjugates (ADCs) comprising a bispecific antibody or...